Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do unsuppressed HIV infections fuel new cases in ethiopia?

NCT ID NCT05652400

Knowledge-focused Sponsor: Lund University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers in Ethiopia are studying how HIV spreads among people with different treatment histories. They compare newly diagnosed individuals who have never taken antiretroviral therapy with those on therapy who have not achieved viral suppression, and with those who are virally suppressed. By analyzing viral genetic sequences, they aim to see whether unsuppressed individuals transmit HIV and whether drug-resistant viruses are spreading. The study also tracks factors behind treatment failure and drug resistance over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Observational study comparing people with HIV who are newly diagnosed, those on antiretroviral therapy without viral suppression, and those with viral suppression. No intervention is given.
What this could lead to
If it works, this could guide public health strategies to reduce HIV transmission and drug resistance in high-prevalence areas.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not apply to other regions with different HIV strains or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,200 people

The number who actually took part.

Started

Jul 2022

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People with HIV. Two categories of participants will be included: 1) persons with no prior or current exposure to antiretroviral therapy; 2) persons with prior or current exposure to antiretroviral therapy. From the latter group, all persons with detectable viremia will be included, with a similar total number of persons with viral suppression (and with no previous recorded lack of viral suppression during antiretroviral therapy).

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Written informed consent Positive HIV test result Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiretroviral therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiretroviral therapy HIV-1-infection

Contacts and locations

Locations

  • Public hospitals and health centers in the Adama uptake area

    Ādama, Oromiya, Ethiopia

More trials for these conditions

Other studies related to the condition(s) this trial covers.